Pharmacology/Pharmaceutical Industry
Remdesivir Shows Modest Improvement in Moderate COVID-19 Patients
2 Jun, 2020 | 04:59h | UTC- Gilead’s remdesivir shows modest improvement in moderate COVID-19 patients – Reuters
- Expert reaction to press release announcing results of stage 3 trial of Gilead’s antiviral remdesivir in moderate patients – Science Media Centre
- Gilead’s remdesivir shows some benefit in patients with moderate Covid-19, new data show – STAT
An Open Letter to Mehra et al and The Lancet
1 Jun, 2020 | 03:58h | UTCAn open letter to Mehra et al and The Lancet – Zenodo
See also: Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere – The Scientist AND A Study Out of Thin Air – Medicine (Un)Censored
Study: Ramipril in High Risk Patients with COVID-19
1 Jun, 2020 | 03:53h | UTCRamipril in High Risk Patients with COVID-19 – Journal of the American College of Cardiology
[Abstract Only] #ASCO20 – Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
1 Jun, 2020 | 03:32h | UTC
[Abstract Only] #ASCO20 – Randomized Trial: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
1 Jun, 2020 | 03:33h | UTC
[Abstract Only] Meta-Analysis: Reappraisal of the Treatment Duration of Antibiotic Regimens for Acute Uncomplicated Cystitis in Adult Women
1 Jun, 2020 | 03:31h | UTCReappraisal of the treatment duration of antibiotic regimens for acute uncomplicated cystitis in adult women: a systematic review and network meta-analysis of 61 randomised clinical trials – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Related Commentary on Twitter
New research Article: Reappraisal of the treatment duration of antibiotic regimens for acute uncomplicated cystitis in adult women: a systematic review and network meta-analysis of 61 randomised clinical trials #UTI https://t.co/klr2k9JFI1 pic.twitter.com/K1nPd5QCxc
— The Lancet Infectious Diseases (@TheLancetInfDis) May 21, 2020
Opinion: Ethical Guidelines for Deliberately Infecting Volunteers with COVID-19 to Speed Vaccine Development
29 May, 2020 | 03:19h | UTCEthical guidelines for deliberately infecting volunteers with COVID-19 – Journal of Medical Ethics
Related: Challenge trials can speed development of a Covid-19 vaccine. Planning for them needs to start now – STAT AND AstraZeneca says it may consider exposing vaccine trial participants to virus – Reuters
[Abstract Only] Meta-Analysis: Postoperative Continuation of Antibiotic Prophylaxis Does Not Reduce the Incidence of Surgical Site Infections
29 May, 2020 | 03:09h | UTC
Meta-Analysis: Direct Oral Anticoagulants vs. Low‐molecular‐weight Heparin for the Treatment of Cancer‐associated Thrombosis
29 May, 2020 | 03:03h | UTC“In patients with cancer‐associated VTE, DOACs are more effective in preventing recurrent VTE compared to LMWH. However, risk of bleeding is increased with DOACs, especially in patients with GI cancer.”
Systematic Review: Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19
28 May, 2020 | 09:59h | UTC
Remdesivir for Covid-19: A 5-day Course is Similarly Effective as a 10-day Course
28 May, 2020 | 10:00h | UTCRemdesivir for 5 or 10 Days in Patients with Severe Covid-19 – New England Journal of Medicine
Review of Trials Currently Testing Treatment and Prevention of COVID-19
28 May, 2020 | 09:48h | UTC
Study: Financial Ties Between Leaders of Influential US Professional Medical Associations and Industry
28 May, 2020 | 09:37h | UTCEditorial: Financial relations between leaders of US medical societies and industry – The BMJ
EULAR Recommendations for the Management of Psoriatic Arthritis
28 May, 2020 | 09:31h | UTCEditorial: EULAR PsA management recommendations 2019: can the recommendations be improved?
Commentary: EULAR releases recommendations for PsA management – Medicine Matters
Short Review: Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020
27 May, 2020 | 02:18h | UTCUsing Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020 – JAMA (free for a limited period)
Randomized Trial: Antihypertensive Medication Reduction vs. Usual Care Among Older Adults Taking Multiple Antihypertensive Medications
27 May, 2020 | 02:16h | UTC
Related Commentary on Twitter
Less is more? Our new trial suggests #deprescribing #bloodpressure lowering medications is safe in the short-term in older people with frailty and multimorbidity – see thread for details https://t.co/fLf2Vv42hB #hypertension #RCT @richardjmcmanus @jenniaburt @HomeUrs29 @prof_mant pic.twitter.com/HfScHju6HS
— James Sheppard (@jamessheppard48) May 26, 2020
Meta-Analysis: Vasopressin or Its Analogs are Not Associated with Reduced Mortality Compared to Catecholamines Alone in Patients with Septic Shock
27 May, 2020 | 02:13h | UTCRelated Review: Vasopressin and its analogues in shock states: a review – Annals of Intensive Care (free)
[Abstract Only] Study: Estimating the Lifetime Benefits of a Multi-drug Regimen for Heart Failure
27 May, 2020 | 02:41h | UTCEstimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials – The Lancet (link to abstract – $ for full-text)
Related Commentary on Twitter
NEW Research—Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trialshttps://t.co/XjRPvdU7tK pic.twitter.com/ZAjynxPdAK
— The Lancet (@TheLancet) May 22, 2020
Perspective: “Here’s What Needs to Happen Before We Can All Get Vaccinated for COVID-19”
26 May, 2020 | 09:45h | UTCHere’s what needs to happen before we can all get vaccinated for COVID-19 – CBC
Impact of COVID-19 on Oncology Clinical Trials
26 May, 2020 | 09:40h | UTCImpact of COVID-19 on oncology clinical trials – Nature Reviews Drug Discovery
Commentary: More Than 200 International Cancer Trials Suspended Due to COVID-19 – Medscape (free registration required)
WHO Pauses Hydroxychloroquine Arm Of COVID-19 Clinical Trial Due to Safety Concerns
26 May, 2020 | 09:35h | UTCSee also: WHO halts hydroxychloroquine trial for coronavirus amid safety fears – The Guardian AND WHO Halts Hydroxychloroquine Trial Over Safety Concerns – NPR
Remdesivir for the Treatment of Covid-19 — Preliminary Report
25 May, 2020 | 02:06h | UTCRemdesivir for the Treatment of Covid-19 — Preliminary Report – New England Journal of Medicine
Commentaries: Preliminary report on NIAID trial of remdesivir – PulmCrit AND Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery – National Institutes of Health AND Covid-19 study details benefits of treatment with remdesivir, and also its limitations – STAT
Related Commentary on Twitter (Thread – Click for more)
I finished reading the Remdesivir trial
If you want my thoughts you will have to read this thread
[Thread] pic.twitter.com/GqA30lCOLI
— Vinay Prasad MD MPH (@VPrasadMDMPH) May 23, 2020
Perspective: The World May Be Overestimating the Power of Vaccines
25 May, 2020 | 01:55h | UTCThe world needs Covid-19 vaccines. It may also be overestimating their power – STAT
Hydroxychloroquine and Chloroquine for Covid-19: Large Observational Analysis Finds No Benefit and Possible Harm
25 May, 2020 | 02:03h | UTCCommentaries: Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? – The Lancet AND What a big new study on malaria drugs as Covid-19 treatments tells us — and what it doesn’t – STAT AND Hydroxychloroquine May Cause More Harm Than Benefit To COVID-19 Patients, Says New Lancet Study – Health Policy Watch
Opinion: Why Countries Should Stop Using Anti-malarial Drugs for COVID-19
25 May, 2020 | 02:02h | UTCWhy countries should stop using anti-malarial drugs for COVID-19 – The Conversation